Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest update is out from JW (Cayman) Therapeutics Co. Ltd. ( (HK:2126) ).
JW Therapeutics announced that its CAR-T cell immunotherapy product, Carteyva®, has received Breakthrough Therapy Designation from the National Medical Products Administration of China as a second-line treatment for adults with relapsed or refractory large B-cell lymphoma (r/r LBCL). This designation is based on clinical study results showing significant efficacy and safety, addressing unmet medical needs for patients unsuitable for conventional treatments. The approval strengthens JW Therapeutics’ position in China’s biotechnology sector and enhances its product pipeline’s potential impact on patient care.
More about JW (Cayman) Therapeutics Co. Ltd.
JW (Cayman) Therapeutics Co. Ltd. is an independent biotechnology company that focuses on developing, manufacturing, and commercializing cell immunotherapy products. Founded in 2016, the company has built an integrated platform for product development across hematologic malignancies, solid tumors, and autoimmune diseases. JW Therapeutics is committed to advancing cell immunotherapy in China and beyond, aiming to offer breakthrough treatments and contribute to the development of China’s cell immunotherapy industry.
YTD Price Performance: 0.0%
Average Trading Volume: 560,323
Technical Sentiment Consensus Rating: Buy
Current Market Cap: HK$531.9M
See more data about 2126 stock on TipRanks’ Stock Analysis page.
